Study S001466

Saxenda: Underlying Mechanisms and Clinical Outcomes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02944500
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 28
Start: 2016-11
Primary completion: 2027-06
Lead sponsor: Beth Israel Deaconess Medical Center
Conditions: Obesity
Interventions: DRUG:liraglutide; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

BOLD response to food cues [5 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0001853	Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide. Stefanakis K, Metabolism: clinical and experimental	2026	Randomized trial	PMID 41513169 DOI	cites ClinicalTrials.gov:NCT02944500; registry reference DERIVED:41513169
R0009442	Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. Angelidi AM, Metabolism: clinical and experimental	2023	Randomized trial	PMID 36375643 DOI	cites ClinicalTrials.gov:NCT02944500; registry reference DERIVED:36375643
R0024373	Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. Peradze N, Cardiovascular diabetology	2019	Randomized trial	PMID 31672146 DOI	cites ClinicalTrials.gov:NCT02944500; registry reference DERIVED:31672146